Drw Securities, LLC Regeneron Pharmaceuticals, Inc. Transaction History

Drw Securities, LLC

$3.55 Billion
Q3 2024

A detailed history of Drw Securities, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Drw Securities, LLC holds 228 shares of REGN stock, worth $160,021. This represents 0.01% of its overall portfolio holdings.

Number of Shares

228

Previous 229 0.44%

Holding current value

$160,021

Previous $240,000 0.42%

% of portfolio

0.01%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$1024.09 - $1201.76 $1,024 - $1,201	-1 Reduced 0.44%	228 $239,000
Q2 2024 Aug 13, 2024	SELL	$883.2 - $1071.19 $520,204 - $630,930	-589 Reduced 72.0%	229 $240,000
Q1 2024 May 14, 2024	BUY	$902.69 - $993.35 $738,400 - $812,560	818 New	818 $787,000
Q3 2023 Nov 13, 2023	BUY	$692.45 - $844.37 $330,298 - $402,764	477 New	477 $393,000
Q2 2022 Aug 12, 2022	SELL	$548.35 - $738.84 $217,694 - $293,319	-397 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$595.12 - $698.43 $236,262 - $277,276	397 New	397 $277,000
Q3 2021 Nov 12, 2021	SELL	$574.03 - $680.96 $325,475 - $386,104	-567 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$472.8 - $558.54 $268,077 - $316,692	567 New	567 $317,000
Q2 2020 Aug 14, 2020	SELL	$493.32 - $643.92 $256,526 - $334,838	-520 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$336.18 - $494.43 $174,813 - $257,103	520 New	520 $254,000
Q1 2018 May 14, 2018	SELL	$315.82 - $393.78 $341,085 - $425,282	-1,080 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$358.63 - $469.95 $387,320 - $507,546	1,080	1,080 $406,000

Others Institutions Holding REGN

# of Institutions

1,534

Shares Held

83.6M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $75.2B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Drw Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Drw Securities, LLC with notifications on news.

Account

Drw Securities, LLC Regeneron Pharmaceuticals, Inc. Transaction History